NHS NEL
Demonstration Formulary
Demonstration Formulary
1 Gastro-intestinal system
01-02 Motility stimulants
| Domperidone |
|
Formulary
|
The MHRA has issued new advice for domperidone which states that it is no longer licensed for the relief of nausea and vomiting in children under the age of 12 years or those weighing less than 35kg (16th December 2019). Domperidone is no longer recommended for managing heartburn,bloating and stomach discomfort It should only be used for relief of nausea and vomiting at low doses for short periods (generally upto 1 week) MHRA advice on domperidone |
 MHRA: Domperidone: risk of cardiac side effects (Published 11 December 2014) NICE: Promoting tolerance of enteral feeds in children and young people: domperidone |
|
Links
- MHRA: Domperidone: risk of cardiac side effects (Published 11 December 2014)
- MHRA: Metoclopramide: risk of neurological adverse effects (Published 11 December 2014)
- NICE CG49: Faecal incontinence in adults: management
- NICE CG61 : Irritable bowel syndrome in adults: diagnosis and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE CG99: Constipation in children and young people: diagnosis and management
- NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea
- NICE: Promoting tolerance of enteral feeds in children and young people: domperidone